drugset
drugset / Trial / NCT02206100

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

NCT02206100 ↗

Phase 1/2 Completed 40 enrolled AMAG Pharmaceuticals, Inc.
RandomizedSequentialSingle-blindOther

Summary

PER977 administration following a single dose of enoxaparin

Timeline

Start
2014-04
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciraparantag Small molecule 25 mg —
Subject Ciraparantag Small molecule 100 mg —
Subject Ciraparantag Small molecule 200 mg —
Subject Ciraparantag Small molecule 300 mg —
Background Enoxaparin sodium Other / unclassified — Subcutaneous

Indications

No indication recorded.